SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ranbaxy makes $500 million provision related to US settlement

21 Dec 2011 Evaluate

Ranbaxy has agreed to a settlement with the US Food and Drug Administration (USFDA) and will make a $500 million provision in relation to a Department of Justice (DoJ) probe to resolve a dispute about plant violations.

Ranbaxy Laboratories Ltd. has signed a consent decree with the U.S. Food and Drug Administration (FDA). Ranbaxy has committed to further strengthen procedures and policies to ensure data integrity. It has also agreed to comply with current good manufacturing practices. The company says that the consent decree is subject to approval by the US District Court for the District of Maryland.

Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×